KIM
RPRX icon

Kestra Investment Management’s Royalty Pharma RPRX Stock Holding History

Kestra Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$437K Sell
7,788
-4,530
-37% -$236K 0.01% 339
2026
Q1 		$591K Sell
12,318
-1,674
-12% -$73.3K 0.01% 271
2025
Q4 		$541K Buy
+13,992
New +$534K 0.01% 268
2025
Q2 		– Sell
-19
Closed -$592 – 931
2025
Q1 		$592 Buy
+19
New +$602 ﹤0.01% 860

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kestra Investment Management's RPRX Position: Q2 2026 in Review

Kestra Investment Management reduced its Royalty Pharma (RPRX) stake by 37% in Q2 2026, selling an estimated $236K and leaving 7,788 shares worth $437K. The position accounts for 0.01% of the portfolio, ranked #339.

Kestra Investment Management first reported a position in RPRX in Q1 2025 and has held it in 4 quarters since. The position peaked at $591K in Q1 2026. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Kestra Investment Management held 7,788 shares of Royalty Pharma worth $437K as of Q2 2026.
  • Kestra Investment Management sold 4,530 Royalty Pharma shares in Q2 2026, an estimated $236K.
  • Royalty Pharma made up 0.01% of Kestra Investment Management's portfolio in Q2 2026, its #339 holding.
  • Kestra Investment Management first reported a position in Royalty Pharma in Q1 2025 and has held it in 4 quarters since.
  • Kestra Investment Management's Royalty Pharma position peaked at $591K in Q1 2026.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Kestra Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.